Sweden has widened an existing government assignment to the Dental and Pharmaceutical Benefits Agency (Tandvårds- och läkemedelsförmånsverket, TLV), adding a formal analysis of willingness to pay for medicines. The assignment places Sweden’s value-based medicines framework within a wider policy debate on launch incentives, affordability and access to cost-effective treatments.
The Ministry of Health and Social Affairs (Socialdepartementet) announced the change on 18 June. The government says TLV must analyse whether access to cost-effective medicines within the pharmaceutical benefits system would be affected by a changed willingness to pay for medicines.
Minister for Social Affairs Jakob Forssmed said Sweden needs to examine whether its willingness to pay should change in response to international developments, and how those developments affect the cost of the pharmaceutical benefits system.
TLV already had an assignment to analyse how the Swedish medicine-pricing system is affected by developments in the international pharmaceutical market. That work covers effects on access, costs and company incentives to launch medicines in Sweden. The revised assignment adds analysis of whether identified challenges would be affected by a changed willingness to pay, and how such changes would affect costs in the pharmaceutical benefits system. TLV must submit the final report by 1 December 2026.
The Association of the Research-Based Pharmaceutical Industry (De forskande läkemedelsföretagen, Lif) welcomed the decision. Its chief executive officer Sofia Wallström described the assignment as a signal that the government is taking the changed international environment seriously. Lif linked the issue to patient access to new medicines, Sweden’s position as a life-sciences country and the effect of low prices on launch and investment conditions.
The assignment does not alter TLV’s current decision rules. It does, however, create an official route for examining whether Sweden’s value threshold, launch environment and public expenditure pressures remain aligned. That discussion is likely to sit alongside TLV’s new subsidy and pricing framework, which will apply from 1 October 2026, and may shape later debate on how Sweden handles high-value, high-cost and internationally exposed medicines.
Source: Ministry of Health and Social Affairs; Association of the Research-Based Pharmaceutical Industry, Lif
Link: Regeringen ändrar TLV:s uppdrag – ska även analysera betalningsvilja för läkemedel (The government changes TLV’s assignment – it must also analyse willingness to pay for medicines); Lif välkomnar regeringens beslut om analys av betalningsvilja för läkemedel: “En stark signal” (Lif welcomes the government’s decision on analysis of willingness to pay for medicines: ‘a strong signal’)
Date: 18 June 2026
